Startups
Although the literature suggests this condition may affect 200 people globally, Williams and his team think the numbers are higher.
While the volatility of the market has some shying away from going public, private investment dollars are still rolling in each week. Check out our top picks.
Seattle-based Mozart Therapeutics closed on a $55 million Series A financing round. The company focuses on developing treatments for celiac disease and other immune-related conditions.
Nuravax is developing an Alzheimer’s vaccine to induce therapeutically potent concentrations of antibodies against pathological proteins. Know more here.
Depression is the first indication, but other neurological conditions are being planned.
Investors can take their pick of life sciences companies, with more innovative ideas and treatments being added to pipelines daily. Here’s who brought in the sheaves this week.
Crinetics Pharmaceuticals, along with 5AM Ventures and Frazier Healthcare Partners, announced that it was spinning out a new company, Radionetics Oncology.
Facing thousands of lawsuits related to its talc-based products, life sciences giant Johnson & Johnson is launching a separate subsidiary dubbed LTL Management LLC that will take the brunt of potential legal liabilities.
Genomics veteran Bob Ragusa is taking over GRAIL, a newly-acquired business unit of Illumina, Inc. He is taking over as CEO Hans Bishop steps down from his role.
On Thursday, Tentarix Biotherapeutics announced that it earned $50 million in a Series A financing round, which was co-led by Versant Ventures and Samsara BioCapital.
PRESS RELEASES